Biography

查看Paul 的中文简历 (pdf)

For over four decades, Paul's practice has focused on representing privately owned businesses, with an emphasis on general business counseling, commercial finance, mergers and acquisitions, private equity, venture capital, international trade and cross-border transactions. His multifaceted practice enables him to serve the domestic and international needs of a wide range of clients.

A significant part of Paul's practice is in finance where he regularly represents lenders and borrowers in commercial loan transactions and represents banks on various types of regulatory matters. He has represented numerous banks in responding to supervisory orders issued by the federal and state bank regulatory agencies, including the OCC and the FDIC, and has represented bank directors in civil money penalty proceedings. Paul also handles de novo bank formations, bank acquisitions and change of control transactions. He also counsel clients relating to all aspects of the CARES Act Paycheck Protection Program, including forgiveness, audits and the impact of PPP loans on future transactions.

Paul's practice over the last 20 years has expanded to representing both U.S. companies doing business overseas and foreign companies doing business in the United States in matters involving:

  • International private equity and venture capital transactions.
  • Cross-border structuring.
  • International debt and equity financing transactions
  • Trade and trade finance
  • Sales distribution agreements
  • Cross-border joint ventures.
  • Committee on Foreign Investment in the United States (CFIUS) compliance.

International

Paul co-heads the firm’s China transactional practice and has deep experience doing business with and in China, in addition to other countries. He was part of a Fox Rothschild team that represented Humanwell Pharmaceutical in its $650 million acquisition of U.S.-based Epic Pharmaceutical. He represents numerous Chinese companies doing business in the U.S. and has advised U.S. companies in structuring their operations in China. He has lectured in the U.S., China and elsewhere, and written extensively on U.S.-China foreign direct investment and related business issues.

To view his alerts on China, click this link, and to view some of his scholarly articles on U.S.-China trade, click this link.

查看Paul 的中文简历 (pdf)

For over four decades, Paul's practice has focused on representing privately owned businesses, with an emphasis on general business counseling, commercial finance, mergers and acquisitions, private equity, venture capital, international trade and cross-border transactions. His multifaceted practice enables him to serve the domestic and international needs of a wide range of clients.

A significant part of Paul's practice is in finance where he regularly represents lenders and borrowers in commercial loan transactions and represents banks on various types of regulatory matters. He has represented numerous banks in responding to supervisory orders issued by the federal and state bank regulatory agencies, including the OCC and the FDIC, and has represented bank directors in civil money penalty proceedings. Paul also handles de novo bank formations, bank acquisitions and change of control transactions. He also counsel clients relating to all aspects of the CARES Act Paycheck Protection Program, including forgiveness, audits and the impact of PPP loans on future transactions.

Paul's practice over the last 20 years has expanded to representing both U.S. companies doing business overseas and foreign companies doing business in the United States in matters involving:

  • International private equity and venture capital transactions.
  • Cross-border structuring.
  • International debt and equity financing transactions
  • Trade and trade finance
  • Sales distribution agreements
  • Cross-border joint ventures.
  • Committee on Foreign Investment in the United States (CFIUS) compliance.

International

Paul co-heads the firm’s China transactional practice and has deep experience doing business with and in China, in addition to other countries. He was part of a Fox Rothschild team that represented Humanwell Pharmaceutical in its $650 million acquisition of U.S.-based Epic Pharmaceutical. He represents numerous Chinese companies doing business in the U.S. and has advised U.S. companies in structuring their operations in China. He has lectured in the U.S., China and elsewhere, and written extensively on U.S.-China foreign direct investment and related business issues.

To view his alerts on China, click this link, and to view some of his scholarly articles on U.S.-China trade, click this link.

Before Fox Rothschild

Prior to joining the firm, Paul was counsel to a New England-based regional firm, where he headed its China practice and was a member of its Privately Owned Business, Private Equity, Community Banking and International Practice Groups.

During law school, Paul was an editor of the Connecticut Law Review.

Beyond Fox Rothschild

Paul is an active member of the American Bar Association’s International Law Section, where he serves on its Governing Council. He previously served as Deputy to the Section Chair, Co-Chair of the Section’s 2025 Annual Conference, Co-Chair of the Section’s Central/East Asia & China Committee and Chair of the East Asia Division. Paul is also Immediate Past President of the Connecticut China Council. He is involved in China civic activities.

Paul lectures and writes frequently on various China legal topics.

Bar Admissions

  • Connecticut
  • New York

Education

  • University of Connecticut School of Law (J.D., with honors, 1976)
  • Wesleyan University (B.A., 1972)

Memberships

  • American Bar Association, International Law Section and Business Law Section
  • Connecticut Bar Association 
  • Fairfield County Bar Association
  • Association for Corporate Growth (ACG)
  • Connecticut District Export Council
  • Connecticut China Council